The Peptide Encyclopedia
Independent, sourced profiles of 30+ peptides. Each entry flags regulatory status honestly β approved medicine, research chemical, or somewhere in between β and links to primary research.
7 peptides
A small-molecule NNMT inhibitor (not a peptide) studied in preclinical metabolic research; included for completeness as it is commonly grouped with research peptides.
Adipotide (also known as Prohibitin-TP01) is a peptide catalogued under Weight Loss & Metabolic (Pro-apoptotic peptide). It is described as: Prohibitin (adipose vasculature). Documented context: Obesity (preclinical). Neutral reference entry; EU status: not approved for human use (research use only).
A modified fragment of human growth hormone (176-191) investigated for fat-metabolism effects; failed to show significant weight-loss efficacy in trials.
Pramlintide (also known as Symlin) is a peptide catalogued under Weight Loss & Metabolic (Amylin analogue). It is described as: Amylin receptor agonist. Documented context: Diabetes mellitus. Neutral reference entry; EU status: EU-approved prescription medicine.
An investigational triple GIP/GLP-1/glucagon receptor agonist in late-stage clinical trials for obesity; not yet approved.
A GLP-1 receptor agonist approved for type 2 diabetes (Ozempic/Rybelsus) and chronic weight management (Wegovy). One of the most rigorously trialed metabolic drugs.
A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes (Mounjaro) and weight management (Zepbound), with large phase-3 trial programs.